Galactomannan detection from piperacillin-tazobactam brands available in the Brazilian market
Braz. j. infect. dis
;
13(5): 353-355, Oct. 2009. tab
Article
in English
| LILACS
| ID: lil-544988
ABSTRACT
Piperacillin-tazobactam is a broad spectrum antimicrobial agent that can cause false-positive results in the commercial Platelia Aspergillus EIA test. So far, no study has been performed in Latin America to evaluate the clinical implication of this finding. Here we studied the potential for galactomannan detection in piperacillin-tazobactam batches commercialized in the Brazilian market. Five batches from distinct laboratories were tested in duplicate in the Platelia Aspergillus EIA according to the manufacturer's instructions. Only one drug showed crossreaction at a cut-off of 0.5. Human serum was spiked with this particular drug aiming to mimic achievable piperacillin-tazobactam concentrations in the serum. Results were all negative for galactomannan detection, even at high drug concentrations. Results from this pilot study suggest that piperacillin-tazobactam might not be a clinically significant cause of false-positive results in the Platelia Aspergillus EIA test in Brazil.
Full text:
Available
Index:
LILACS (Americas)
Main subject:
Aspergillus
/
Immunoenzyme Techniques
/
Mannans
/
Anti-Bacterial Agents
Type of study:
Diagnostic study
/
Evaluation studies
Country/Region as subject:
South America
/
Brazil
Language:
English
Journal:
Braz. j. infect. dis
Journal subject:
Communicable Diseases
Year:
2009
Type:
Article
Affiliation country:
Brazil
Institution/Affiliation country:
Brazilian government/BR
/
Santa Casa Complexo Hospitalar/BR
/
Universidade Federal do Rio Grande do Sul/BR
Similar
MEDLINE
...
LILACS
LIS